Condition: Bone Sarcoma · Osteosarcoma · Ewing Sarcoma · Sponsor: Centre Leon Berard
Randomized, non-comparative, multicentre exploratory phase II study. Two arms concerning patients with bone sarcoma after the first line therapy: in the first arm, patients will be treated with Regorafenib for a maximum of 12 months as maintenance therapy after first line therapy, whereas in the second arm, patients will be kept under surveillance (standard of care). Regardless of their study arm, all the patients will be followed up until end of the study. The comparison between these two arms will allow to determine whether or not regorafenib is efficient for disease control, in terms of Relapse-Free Survival improvement.
This description comes directly from the study's public registry record.
Julien GAUTIER · +33 426 55 68 29 · julien.gautier@lyon.unicancer.fr
Always discuss trial participation with your own doctor first.
| Hôpital Jean Minjoz | Besançon, France | Recruiting |
| Institut Bergonié | Bordeaux, France | Recruiting |
| Centre Oscar Lambret | Lille, France | Recruiting |
| Centre Léon Bérard | Lyon, France | Recruiting |
| APHM - Hôpital Timone | Marseille, France | Recruiting |
| ICM Val d'Aurelle | Montpellier, France | Not Yet Recruiting |
| Institut Curie | Paris, France | Recruiting |
| APHP Hôpital Cochin | Paris, France | Recruiting |
| Centre Hospitalier Universitaire de Poitiers | Poitiers, France | Not Yet Recruiting |
| Centre Hospitalier Universitaire de Saint-Etienne (CHUSE) | Saint-Etienne, France | Recruiting |
| ICO René Gauducheau | Saint-Herblain, France | Recruiting |
| Centre Paul Strauss - Strasbourg | Strasbourg, France | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04055220